Saturday, July 5, 2025

Creating liberating content

If you or someone you know experiences any of these

Ayurveda, the ancient Indian system of medicine, isn’t just for

NEW DELHI: India on Friday proposed imposing of retaliatory duties

NEW DELHI: Fair trade regulator CCI has directed Aditya Birla

Related News

If you or someone you know experiences any of these symptoms—particularly in the setting of risk factors like diabetes, high blood pressure, a family history of kidney disease, or long-term

Ayurveda, the ancient Indian system of medicine, isn’t just for adults. Almost everyone in the world right now is stressed, and children are no different. The new age kids of

NEW DELHI: India on Friday proposed imposing of retaliatory duties under WTO norms against the US tariffs on imports of auto parts in the name of safeguard measures.“The proposed suspension

NEW DELHI: Fair trade regulator CCI has directed Aditya Birla firm UltraTech, which now owns south-based cement firm India Cements, along with two other makers and their executives to submit

Gold rose – putting it on track for a 2% weekly gain – as President Donald Trump said some US trading partners would face tariffs from Aug 1. Bullion rose

Smack dab in the Great Salt Lake, Antelope Island sounds like a fantasy setting, and it sort of is. Bison, bighorn sheep, pronghorn antelope (surprise!), and coyotes roam the stark,

Trending News

NEW DELHI: Fair trade regulator CCI has directed Aditya Birla firm UltraTech, which now owns south-based cement firm India Cements, along with two other makers and their executives to submit

CHENNAI: A weak rupee was among the reasons that made foreign currency deposits attractive for NRIs. The net inflow under foreign currency non-resident (B) accounts increased by 11% to $7.1

The free trade agreement between India and the European Free Trade Association (EFTA) is likely to be implemented in the next couple of months, Commerce and Industry Minister Piyush Goyal

India’s Competition watchdog, the Competition Commission of India (CCI) has directed UltraTech Cement — which now controls India Cements — along with Dalmia Bharat and Shree Digvijay Cement, to furnish

Gold rate today: Gold prices declined sharply by Rs 600 to Rs 99,020 per 10 grams in Delhi on Friday, driven by fresh selling from stockists and a stronger US

India has informed the WTO’s Council for Trade in Goods regarding its intended suspension of concessions. (AI image) India has proposed retaliatory tariffs on Friday against the United States at

Top stocks to buy today: Stock recommendations for March 19, 2025

Word Count: 627 | Estimated Reading Time: 4 minutes


Top stocks to buy today: Stock recommendations for March 19, 2025
Top stocks to buy (AI image)

Stock market recommendations: According to Mehul Kothari, DVP – Technical Research, Anand Rathi Shares and Stock Brokers, BHEL, Astrazeneca Pharma and Maruti Suzuki India are the top stock picks for today:
BHEL: BUY Near ₹200 | Stop Loss: ₹175 | Target: ₹250
The stock has confirmed an inverse Head and Shoulders breakout, signaling a trend reversal. The daily RSI is above 50, and the weekly RSI has crossed over positively from the oversold zone, further strengthening the bullish bias. Additionally, the stock is likely to retest its 200 DEMA near ₹250, providing a potential upside.
Thus, traders are advised to buy BHEL in the range of ₹195–₹205, with a stop-loss at ₹175 on a closing basis, for an upside target of ₹250 in the coming months.
ASTRAZENECA PHARMA: BUY Near ₹7900 | Stop Loss: ₹7600 | Target: ₹8500
Despite the market correction, the stock is trading near its lifetime high, indicating strong relative strength. It is on the verge of a fresh breakout, reinforcing its bullish momentum. Additionally, the weekly RSI has confirmed a trendline breakout, signalling further upside potential.
Thus, traders are advised to buy ASTRAZENECA PHARMA in the range of ₹7850–₹7950, with a stop-loss at ₹7600 on a closing basis, for an upside target of ₹8500 in the coming months.
MARUTI: BUY Near ₹11,700 | Stop Loss: ₹11,400 | Target: ₹12,300
In January 2025, the stock gave a breakout above ₹11,500, leading to a rally towards ₹13,500. It has now retested the breakout zone, offering a strong risk-reward setup for a short-term bounce.
Thus, traders are advised to buy MARUTI in the range of ₹11,600–₹11,800, with a stop-loss at ₹11,400 on a closing basis, for an upside target of ₹12,300 in the coming weeks.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.





Source link

Most Popular Articles

Sign In

Welcome ! Log into Your Account